Q2 2025 Management View CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...

CSL (ASX: CSL) shares fell 4.9% on Tuesday following the company’s report of weaker-than-expected first-half revenue, net ...

UBS believes the CSL shares story is "heavily focused on gross profit margin improvement" at Behring. According to CSL, that division develops and delivers "high-quality medicines that treat ...

SCOTTSDALE, Ariz., February 12, 2025--Carlisle Companies Incorporated (NYSE:CSL) is reinforcing its commitment to innovation through the development and execution of its new innovation accelerator ...

Japanese researchers have used a nimble robotic hand exoskeleton to train expert pianists to improve their performance, using ...

Today, the fund is underweight in CSL. Firetail said: Today our position is well below index weight due to our loss of confidence in the medium-term margin improvement story playing out as we had ...